A Pennsylvania jury found that drugmaker Johnson & Johnson failed to warn a man who suffered Risperdal-related gynecomastia and determined the pharmaceutical giant should pay him an eight-figure award. In October 2019, Johnson & Johnson was ordered to pay $8 billion to settle the lawsuit filed by Nicholas M., a Maryland man who claimed that Risperdal caused him to develop breasts. Nicholas's lawsuit was the first Risperdal case to result in punitive damages against the drugmaker.